Author

S. K. Rathe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. A. Largaespada· 2 shared A. L. Sarver· 1 shared B. C. Braman· 1 shared B. R. Tschida· 1 shared C. J. Liu· 1 shared C. L. Moertel· 1 shared D. J. Odde· 1 shared D. Masopust· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. A. Largaespada

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential migration mechanics and immune responses of glioblastoma subtypes

G. A. Shamsan, C. J. Liu, B. C. Braman, R. Li, S. K. Rathe, A. L. Sarver, N. Ghaderi, M. M. McMahon, R. L. Klank, B. R. Tschida, S. J. McFarren, P. C. Rosato, D. Masopust, J. N. Sarkaria, H. B. Clark, , D. J. Odde

This study shows mesenchymal glioblastoma cells migrate faster and generate more traction force than proneural cells, but their immunologically hot environment improves survival despite aggressive growth.

bioRxiv · Jun 26, 2022 · PreprintCancer Biology

CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: A novel approach to glioblastoma immunotherapy

Z. Xiong, E. Ampudia-Mesias, G. E. Pluhar, S. K. Rathe, D. A. Largaespada, Y. Y. Sham, C. L. Moertel, M. R. Olin

This paper demonstrates that a CD200 peptide inhibitor enhances immune response in glioblastoma by reversing tumor-induced immunosuppression and downregulating PD-1 receptors.

bioRxiv · Aug 6, 2019 · PreprintCancer Biology